{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T09:54:26Z","timestamp":1781690066324,"version":"3.54.5"},"reference-count":52,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["CPT Pharmacom &amp; Syst Pharma"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Transthyretin amyloid cardiomyopathy (ATTR\u2010CM) is a progressive, often fatal disease arising from the dissociation of circulating transthyretin (TTR) tetramers into monomers that misfold and form amyloid fibrils that deposit in the myocardium and other tissues. Approved treatment paradigms involve tetramer stabilization with small molecules or TTR knockdown via RNA interference. Despite the clinical success of these drugs across several metrics (including all\u2010cause mortality and cardiovascular hospitalization), gaps remain in understanding how measurable biological changes, such as differences in serum TTR concentration, translate into reductions in amyloid deposition. To address this, we built a mechanistic mathematical model of the TTR system that integrates heterogeneous data sources, including in\u00a0vitro assays and clinical data, and recapitulates key features of ATTR\u2010CM disease biology. The model predicts \u201cmonomer efflux,\u201d the rate at which unfolded monomers could potentially form amyloid, as a proxy for the pathogenic mechanism, which is difficult to measure. Model\u2010predicted monomer efflux linearly correlated with reported rates of change in clinical measures, supporting its validity as a comparative metric. The model showed that monomer efflux is nearly twice as high in hereditary ATTR\u2010CM (ATTRv) as in wild\u2010type ATTR\u2010CM (ATTRwt). Comparison of treatment modalities showed that acoramidis yields the greatest reduction in monomer efflux (96% in ATTRwt, 95% in ATTRv) due to rapid, near\u2010complete stabilization of TTR. This framework enables quantitative interrogation of the disease system and principled comparisons across modalities that may help inform treatment selection.<\/jats:p>","DOI":"10.1002\/psp4.70277","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:56:12Z","timestamp":1780923372000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the Current\n                    <scp>ATTR<\/scp>\n                    \u2010\n                    <scp>CM<\/scp>\n                    Treatment Landscape via a Mathematical Model of\n                    <scp>TTR<\/scp>\n                    Dissociation and Amyloid Formation"],"prefix":"10.1002","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3352-5386","authenticated-orcid":false,"given":"Stevan","family":"Methven Jekni\u0107","sequence":"first","affiliation":[{"name":"BridgeBio Pharma, Inc  Palo Alto California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3049-3366","authenticated-orcid":false,"given":"Travis A.","family":"Ahn\u2010Horst","sequence":"additional","affiliation":[{"name":"BridgeBio Pharma, Inc  Palo Alto California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8086-3952","authenticated-orcid":false,"given":"Alan X.","family":"Ji","sequence":"additional","affiliation":[{"name":"BridgeBio Pharma, Inc  Palo Alto California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1247-8055","authenticated-orcid":false,"given":"Jin Hyun","family":"Ju","sequence":"additional","affiliation":[{"name":"BridgeBio Pharma, Inc  Palo Alto California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6852-1636","authenticated-orcid":false,"given":"Morgan","family":"Paull","sequence":"additional","affiliation":[{"name":"GondolaBio Pharma, Inc  Palo Alto California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8652-6318","authenticated-orcid":false,"given":"Sun\u2010Gou","family":"Ji","sequence":"additional","affiliation":[{"name":"BridgeBio Pharma, Inc  Palo Alto California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Sinha","sequence":"additional","affiliation":[{"name":"BridgeBio Pharma, Inc  Palo Alto California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.0442"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/78980"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M101024200"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.7.2843"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08609-z"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.261419998"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.202495199"},{"key":"e_1_2_9_9_1","unstructured":"D.RowczenioandA.Wechalekar \u201cMutations in Hereditary Amyloidosis \u201d(2015) http:\/\/amyloidosismutations.com\/."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.596"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506120802525285"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1997.00662.x"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.5969"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.113.301273"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305434"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409134"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-024-10444-4"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716153"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.03.542"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2022.2145876"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3455"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-35000-y"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics18030367"},{"key":"e_1_2_9_25_1","article-title":"LMFIT: Non\u2010Linear Least\u2010Squares Minimization and Curve\u2010Fitting for Python (v1.3.4)","author":"Newville M.","year":"2025","journal-title":"Zenodo"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2022.2091985"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2020.09.011"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2025.4477"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.21105\/joss.00097"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1300761110"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1121005109"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1137188100"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja104999v"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00817"},{"key":"e_1_2_9_35_1","volume-title":"Prescribing Information, Attruby (Acoramidis)","author":"BridgeBio Pharma, Inc","year":"2024"},{"key":"e_1_2_9_36_1","volume-title":"Prescribing Information, Vyndaqel\/Vyndamax (Tafamidis)","author":"Pfizer, Inc","year":"2019"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2020.1808783"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2016.5864"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004000"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI105266"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.149.3685.748"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi800636q"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi500171j"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2016072118"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.3109\/13506120108993822"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae811"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathophysiology29030025"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx589"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2024.4578"},{"key":"e_1_2_9_50_1","first-page":"1906","article-title":"The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism","volume":"10","author":"Sanguinetti C.","year":"2022","journal-title":"Biomedicine"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3094"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccl.2024.09.006"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.241406698"}],"container-title":["CPT: Pharmacometrics &amp; Systems Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.70277","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/psp4.70277","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.70277","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T09:08:04Z","timestamp":1781687284000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/psp4.70277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/psp4.70277"],"URL":"https:\/\/doi.org\/10.1002\/psp4.70277","archive":["Portico"],"relation":{},"ISSN":["2163-8306","2163-8306"],"issn-type":[{"value":"2163-8306","type":"print"},{"value":"2163-8306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2026-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70277"}}